Pharvaris NV (PHVS)
37.92
+0.18
(+0.48%)
USD |
NASDAQ |
Sep 10, 13:49
Pharvaris Enterprise Value : 2.286B for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 2.286B |
| September 08, 2026 | 2.293B |
| September 04, 2026 | 2.112B |
| September 03, 2026 | 2.140B |
| September 02, 2026 | 2.106B |
| September 01, 2026 | 2.089B |
| August 31, 2026 | 2.067B |
| August 28, 2026 | 2.117B |
| August 27, 2026 | 2.234B |
| August 26, 2026 | 2.234B |
| August 25, 2026 | 2.251B |
| August 24, 2026 | 2.256B |
| August 21, 2026 | 2.183B |
| August 20, 2026 | 2.192B |
| August 19, 2026 | 2.183B |
| August 18, 2026 | 2.171B |
| August 17, 2026 | 2.117B |
| August 14, 2026 | 2.104B |
| August 13, 2026 | 2.027B |
| August 12, 2026 | 2.197B |
| August 11, 2026 | 2.053B |
| August 10, 2026 | 2.083B |
| August 07, 2026 | 2.088B |
| August 06, 2026 | 2.055B |
| August 05, 2026 | 1.983B |
| Date | Value |
|---|---|
| August 04, 2026 | 2.015B |
| August 03, 2026 | 1.901B |
| July 31, 2026 | 1.927B |
| July 30, 2026 | 2.015B |
| July 29, 2026 | 1.927B |
| July 28, 2026 | 1.999B |
| July 27, 2026 | 2.022B |
| July 24, 2026 | 2.036B |
| July 23, 2026 | 1.972B |
| July 22, 2026 | 2.049B |
| July 21, 2026 | 2.055B |
| July 20, 2026 | 1.992B |
| July 17, 2026 | 2.090B |
| July 16, 2026 | 2.000B |
| July 15, 2026 | 2.105B |
| July 14, 2026 | 2.053B |
| July 13, 2026 | 2.099B |
| July 10, 2026 | 2.099B |
| July 09, 2026 | 2.161B |
| July 08, 2026 | 2.159B |
| July 07, 2026 | 2.065B |
| July 06, 2026 | 1.969B |
| July 02, 2026 | 2.014B |
| July 01, 2026 | 2.020B |
| June 30, 2026 | 2.065B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 293.39B |
| BioAge Labs, Inc. | 103.86M |
| AstraZeneca PLC | 513.07B |
| ANI Pharmaceuticals, Inc. | 1.859B |
| Corcept Therapeutics, Inc. | 12.19B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.63M |
| Total Expenses (Quarterly) | 55.63M |
| EPS Diluted (Quarterly) | -0.8172 |
| Earnings Yield | -8.05% |
| Normalized Earnings Yield | -8.045 |